IMAC Holdings, Inc.
IMAC Holdings, Inc. (IMAC) Stock Competitors & Peer Comparison
See (IMAC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IMAC | $1.01 | +2.00% | 33.1M | -2.27 | -$0.45 | N/A |
| HCA | $526.52 | +0.00% | 120.9B | 19.08 | $28.32 | +0.53% |
| THC | $237.58 | +0.00% | 20.8B | 15.29 | $15.50 | N/A |
| UHS | $229.98 | +0.00% | 14.9B | 10.97 | $21.02 | +0.34% |
| FMS | $22.66 | +0.00% | 13.2B | 15.74 | $1.44 | +3.47% |
| SOLV | $73.42 | +0.00% | 13B | 8.62 | $8.71 | N/A |
| ENSG | $212.39 | +0.00% | 12.4B | 36.68 | $5.83 | +0.12% |
| EHC | $104.84 | +0.00% | 10.7B | 19.13 | $5.55 | +0.68% |
| DVA | $150.91 | +0.00% | 10B | 15.72 | $9.51 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
IMAC vs HCA Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, HCA has a market cap of 120.9B. Regarding current trading prices, IMAC is priced at $1.01, while HCA trades at $526.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas HCA's P/E ratio is 19.08. In terms of profitability, IMAC's ROE is +1183.61%, compared to HCA's ROE of -1.41%. Regarding short-term risk, IMAC is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check HCA's competition here
IMAC vs THC Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, THC has a market cap of 20.8B. Regarding current trading prices, IMAC is priced at $1.01, while THC trades at $237.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas THC's P/E ratio is 15.29. In terms of profitability, IMAC's ROE is +1183.61%, compared to THC's ROE of +0.35%. Regarding short-term risk, IMAC is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check THC's competition here
IMAC vs UHS Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, UHS has a market cap of 14.9B. Regarding current trading prices, IMAC is priced at $1.01, while UHS trades at $229.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas UHS's P/E ratio is 10.97. In terms of profitability, IMAC's ROE is +1183.61%, compared to UHS's ROE of +0.20%. Regarding short-term risk, IMAC is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check UHS's competition here
IMAC vs FMS Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, FMS has a market cap of 13.2B. Regarding current trading prices, IMAC is priced at $1.01, while FMS trades at $22.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas FMS's P/E ratio is 15.74. In terms of profitability, IMAC's ROE is +1183.61%, compared to FMS's ROE of +0.05%. Regarding short-term risk, IMAC is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check FMS's competition here
IMAC vs SOLV Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, SOLV has a market cap of 13B. Regarding current trading prices, IMAC is priced at $1.01, while SOLV trades at $73.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas SOLV's P/E ratio is 8.62. In terms of profitability, IMAC's ROE is +1183.61%, compared to SOLV's ROE of +0.41%. Regarding short-term risk, IMAC is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check SOLV's competition here
IMAC vs ENSG Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, ENSG has a market cap of 12.4B. Regarding current trading prices, IMAC is priced at $1.01, while ENSG trades at $212.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas ENSG's P/E ratio is 36.68. In terms of profitability, IMAC's ROE is +1183.61%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, IMAC is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check ENSG's competition here
IMAC vs EHC Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, EHC has a market cap of 10.7B. Regarding current trading prices, IMAC is priced at $1.01, while EHC trades at $104.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas EHC's P/E ratio is 19.13. In terms of profitability, IMAC's ROE is +1183.61%, compared to EHC's ROE of +0.23%. Regarding short-term risk, IMAC is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check EHC's competition here
IMAC vs DVA Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, DVA has a market cap of 10B. Regarding current trading prices, IMAC is priced at $1.01, while DVA trades at $150.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas DVA's P/E ratio is 15.72. In terms of profitability, IMAC's ROE is +1183.61%, compared to DVA's ROE of -1.61%. Regarding short-term risk, IMAC is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check DVA's competition here
IMAC vs OSH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, IMAC is priced at $1.01, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas OSH's P/E ratio is -17.65. In terms of profitability, IMAC's ROE is +1183.61%, compared to OSH's ROE of +4.64%. Regarding short-term risk, IMAC is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check OSH's competition here
IMAC vs CHE Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, IMAC is priced at $1.01, while CHE trades at $468.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CHE's P/E ratio is 24.66. In terms of profitability, IMAC's ROE is +1183.61%, compared to CHE's ROE of +0.24%. Regarding short-term risk, IMAC is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check CHE's competition here
IMAC vs OPCH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, OPCH has a market cap of 5.5B. Regarding current trading prices, IMAC is priced at $1.01, while OPCH trades at $33.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas OPCH's P/E ratio is 26.67. In terms of profitability, IMAC's ROE is +1183.61%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, IMAC is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check OPCH's competition here
IMAC vs LHCG Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, IMAC is priced at $1.01, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas LHCG's P/E ratio is 82.83. In terms of profitability, IMAC's ROE is +1183.61%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, IMAC is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check LHCG's competition here
IMAC vs BKD Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, BKD has a market cap of 3.6B. Regarding current trading prices, IMAC is priced at $1.01, while BKD trades at $15.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas BKD's P/E ratio is -11.44. In terms of profitability, IMAC's ROE is +1183.61%, compared to BKD's ROE of -5.24%. Regarding short-term risk, IMAC is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check BKD's competition here
IMAC vs AMED Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, IMAC is priced at $1.01, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AMED's P/E ratio is 39.30. In terms of profitability, IMAC's ROE is +1183.61%, compared to AMED's ROE of +0.13%. Regarding short-term risk, IMAC is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check AMED's competition here
IMAC vs LFST Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, LFST has a market cap of 2.9B. Regarding current trading prices, IMAC is priced at $1.01, while LFST trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas LFST's P/E ratio is -247.00. In terms of profitability, IMAC's ROE is +1183.61%, compared to LFST's ROE of -0.01%. Regarding short-term risk, IMAC is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check LFST's competition here
IMAC vs NHC Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, NHC has a market cap of 2.5B. Regarding current trading prices, IMAC is priced at $1.01, while NHC trades at $157.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas NHC's P/E ratio is 24.80. In terms of profitability, IMAC's ROE is +1183.61%, compared to NHC's ROE of +0.10%. Regarding short-term risk, IMAC is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check NHC's competition here
IMAC vs SGRY Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, SGRY has a market cap of 2B. Regarding current trading prices, IMAC is priced at $1.01, while SGRY trades at $15.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas SGRY's P/E ratio is -11.39. In terms of profitability, IMAC's ROE is +1183.61%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, IMAC is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check SGRY's competition here
IMAC vs ADUS Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, ADUS has a market cap of 2B. Regarding current trading prices, IMAC is priced at $1.01, while ADUS trades at $105.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas ADUS's P/E ratio is 23.10. In terms of profitability, IMAC's ROE is +1183.61%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, IMAC is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check ADUS's competition here
IMAC vs ACHC Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, ACHC has a market cap of 1.9B. Regarding current trading prices, IMAC is priced at $1.01, while ACHC trades at $17.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas ACHC's P/E ratio is 17.95. In terms of profitability, IMAC's ROE is +1183.61%, compared to ACHC's ROE of -0.39%. Regarding short-term risk, IMAC is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check ACHC's competition here
IMAC vs SEM Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, SEM has a market cap of 1.8B. Regarding current trading prices, IMAC is priced at $1.01, while SEM trades at $14.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas SEM's P/E ratio is 18.16. In terms of profitability, IMAC's ROE is +1183.61%, compared to SEM's ROE of +0.09%. Regarding short-term risk, IMAC is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check SEM's competition here
IMAC vs AMEH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, IMAC is priced at $1.01, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AMEH's P/E ratio is 39.25. In terms of profitability, IMAC's ROE is +1183.61%, compared to AMEH's ROE of +0.02%. Regarding short-term risk, IMAC is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check AMEH's competition here
IMAC vs MD Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, MD has a market cap of 1.7B. Regarding current trading prices, IMAC is priced at $1.01, while MD trades at $20.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas MD's P/E ratio is 10.42. In terms of profitability, IMAC's ROE is +1183.61%, compared to MD's ROE of +0.20%. Regarding short-term risk, IMAC is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check MD's competition here
IMAC vs HCSG Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, IMAC is priced at $1.01, while HCSG trades at $21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas HCSG's P/E ratio is 26.64. In terms of profitability, IMAC's ROE is +1183.61%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, IMAC is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check HCSG's competition here
IMAC vs AVAH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AVAH has a market cap of 1.5B. Regarding current trading prices, IMAC is priced at $1.01, while AVAH trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AVAH's P/E ratio is 19.49. In terms of profitability, IMAC's ROE is +1183.61%, compared to AVAH's ROE of -1.36%. Regarding short-term risk, IMAC is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check AVAH's competition here
IMAC vs ARDT Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, ARDT has a market cap of 1.4B. Regarding current trading prices, IMAC is priced at $1.01, while ARDT trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas ARDT's P/E ratio is 6.66. In terms of profitability, IMAC's ROE is +1183.61%, compared to ARDT's ROE of +0.17%. Regarding short-term risk, IMAC is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check ARDT's competition here
IMAC vs USPH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, IMAC is priced at $1.01, while USPH trades at $82.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas USPH's P/E ratio is 34.40. In terms of profitability, IMAC's ROE is +1183.61%, compared to USPH's ROE of +0.07%. Regarding short-term risk, IMAC is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check USPH's competition here
IMAC vs BKDT Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, IMAC is priced at $1.01, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas BKDT's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, IMAC is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check BKDT's competition here
IMAC vs INNV Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, INNV has a market cap of 1.2B. Regarding current trading prices, IMAC is priced at $1.01, while INNV trades at $8.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas INNV's P/E ratio is 178.00. In terms of profitability, IMAC's ROE is +1183.61%, compared to INNV's ROE of -0.02%. Regarding short-term risk, IMAC is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check INNV's competition here
IMAC vs PNTG Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, IMAC is priced at $1.01, while PNTG trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas PNTG's P/E ratio is 44.12. In terms of profitability, IMAC's ROE is +1183.61%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, IMAC is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check PNTG's competition here
IMAC vs ASTH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, ASTH has a market cap of 1B. Regarding current trading prices, IMAC is priced at $1.01, while ASTH trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas ASTH's P/E ratio is 105.00. In terms of profitability, IMAC's ROE is +1183.61%, compared to ASTH's ROE of +0.01%. Regarding short-term risk, IMAC is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check ASTH's competition here
IMAC vs FSHCX Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, FSHCX has a market cap of 808M. Regarding current trading prices, IMAC is priced at $1.01, while FSHCX trades at $98.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas FSHCX's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to FSHCX's ROE of N/A. Regarding short-term risk, IMAC is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check FSHCX's competition here
IMAC vs AMN Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AMN has a market cap of 768.7M. Regarding current trading prices, IMAC is priced at $1.01, while AMN trades at $20.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AMN's P/E ratio is -2.78. In terms of profitability, IMAC's ROE is +1183.61%, compared to AMN's ROE of -0.15%. Regarding short-term risk, IMAC is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check AMN's competition here
IMAC vs TALK Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, TALK has a market cap of 760.3M. Regarding current trading prices, IMAC is priced at $1.01, while TALK trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas TALK's P/E ratio is 151.33. In terms of profitability, IMAC's ROE is +1183.61%, compared to TALK's ROE of +0.07%. Regarding short-term risk, IMAC is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check TALK's competition here
IMAC vs CMPS Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CMPS has a market cap of 714.3M. Regarding current trading prices, IMAC is priced at $1.01, while CMPS trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CMPS's P/E ratio is -2.74. In terms of profitability, IMAC's ROE is +1183.61%, compared to CMPS's ROE of -1.72%. Regarding short-term risk, IMAC is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check CMPS's competition here
IMAC vs EHAB Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, EHAB has a market cap of 688.9M. Regarding current trading prices, IMAC is priced at $1.01, while EHAB trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas EHAB's P/E ratio is -56.62. In terms of profitability, IMAC's ROE is +1183.61%, compared to EHAB's ROE of -0.02%. Regarding short-term risk, IMAC is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check EHAB's competition here
IMAC vs SNDA Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, SNDA has a market cap of 661.8M. Regarding current trading prices, IMAC is priced at $1.01, while SNDA trades at $35.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas SNDA's P/E ratio is -11.79. In terms of profitability, IMAC's ROE is +1183.61%, compared to SNDA's ROE of -0.44%. Regarding short-term risk, IMAC is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check SNDA's competition here
IMAC vs CYH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CYH has a market cap of 504.2M. Regarding current trading prices, IMAC is priced at $1.01, while CYH trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CYH's P/E ratio is 1.49. In terms of profitability, IMAC's ROE is +1183.61%, compared to CYH's ROE of -0.32%. Regarding short-term risk, IMAC is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check CYH's competition here
IMAC vs MCTA Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, IMAC is priced at $1.01, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas MCTA's P/E ratio is 419.36. In terms of profitability, IMAC's ROE is +1183.61%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, IMAC is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check MCTA's competition here
IMAC vs AUNA Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AUNA has a market cap of 376.1M. Regarding current trading prices, IMAC is priced at $1.01, while AUNA trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AUNA's P/E ratio is 5.13. In terms of profitability, IMAC's ROE is +1183.61%, compared to AUNA's ROE of +0.12%. Regarding short-term risk, IMAC is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check AUNA's competition here
IMAC vs AONC Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AONC has a market cap of 351M. Regarding current trading prices, IMAC is priced at $1.01, while AONC trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AONC's P/E ratio is -13.48. In terms of profitability, IMAC's ROE is +1183.61%, compared to AONC's ROE of -0.02%. Regarding short-term risk, IMAC is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check AONC's competition here
IMAC vs CCRN Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CCRN has a market cap of 292.5M. Regarding current trading prices, IMAC is priced at $1.01, while CCRN trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CCRN's P/E ratio is -18.22. In terms of profitability, IMAC's ROE is +1183.61%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, IMAC is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check CCRN's competition here
IMAC vs TOI Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, TOI has a market cap of 281.4M. Regarding current trading prices, IMAC is priced at $1.01, while TOI trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas TOI's P/E ratio is -4.47. In terms of profitability, IMAC's ROE is +1183.61%, compared to TOI's ROE of +21.04%. Regarding short-term risk, IMAC is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check TOI's competition here
IMAC vs CSU Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, IMAC is priced at $1.01, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CSU's P/E ratio is 0.67. In terms of profitability, IMAC's ROE is +1183.61%, compared to CSU's ROE of -3.25%. Regarding short-term risk, IMAC is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check CSU's competition here
IMAC vs AGL Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AGL has a market cap of 210.8M. Regarding current trading prices, IMAC is priced at $1.01, while AGL trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AGL's P/E ratio is -0.65. In terms of profitability, IMAC's ROE is +1183.61%, compared to AGL's ROE of -0.73%. Regarding short-term risk, IMAC is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check AGL's competition here
IMAC vs JYNT Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, JYNT has a market cap of 140.9M. Regarding current trading prices, IMAC is priced at $1.01, while JYNT trades at $9.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas JYNT's P/E ratio is -928.00. In terms of profitability, IMAC's ROE is +1183.61%, compared to JYNT's ROE of -0.04%. Regarding short-term risk, IMAC is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check JYNT's competition here
IMAC vs NAKAW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, IMAC is priced at $1.01, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas NAKAW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to NAKAW's ROE of -0.74%. Regarding short-term risk, IMAC is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check NAKAW's competition here
IMAC vs AIRS Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AIRS has a market cap of 112.4M. Regarding current trading prices, IMAC is priced at $1.01, while AIRS trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AIRS's P/E ratio is -6.00. In terms of profitability, IMAC's ROE is +1183.61%, compared to AIRS's ROE of -0.22%. Regarding short-term risk, IMAC is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check AIRS's competition here
IMAC vs BTMD Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, BTMD has a market cap of 101.4M. Regarding current trading prices, IMAC is priced at $1.01, while BTMD trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas BTMD's P/E ratio is 2.68. In terms of profitability, IMAC's ROE is +1183.61%, compared to BTMD's ROE of -0.33%. Regarding short-term risk, IMAC is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check BTMD's competition here
IMAC vs FVE Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, IMAC is priced at $1.01, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas FVE's P/E ratio is -5.64. In terms of profitability, IMAC's ROE is +1183.61%, compared to FVE's ROE of -0.15%. Regarding short-term risk, IMAC is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check FVE's competition here
IMAC vs KDLYW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, IMAC is priced at $1.01, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas KDLYW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to KDLYW's ROE of -0.74%. Regarding short-term risk, IMAC is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check KDLYW's competition here
IMAC vs DCGO Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, DCGO has a market cap of 70.4M. Regarding current trading prices, IMAC is priced at $1.01, while DCGO trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas DCGO's P/E ratio is -1.36. In terms of profitability, IMAC's ROE is +1183.61%, compared to DCGO's ROE of -0.17%. Regarding short-term risk, IMAC is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check DCGO's competition here
IMAC vs ALR Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, IMAC is priced at $1.01, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas ALR's P/E ratio is -1.11. In terms of profitability, IMAC's ROE is +1183.61%, compared to ALR's ROE of -0.15%. Regarding short-term risk, IMAC is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check ALR's competition here
IMAC vs CCEL Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CCEL has a market cap of 27.3M. Regarding current trading prices, IMAC is priced at $1.01, while CCEL trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CCEL's P/E ratio is -56.50. In terms of profitability, IMAC's ROE is +1183.61%, compared to CCEL's ROE of -0.03%. Regarding short-term risk, IMAC is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check CCEL's competition here
IMAC vs AIH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, IMAC is priced at $1.01, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AIH's P/E ratio is -2.78. In terms of profitability, IMAC's ROE is +1183.61%, compared to AIH's ROE of +1.16%. Regarding short-term risk, IMAC is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check AIH's competition here
IMAC vs AMS Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, AMS has a market cap of 14.1M. Regarding current trading prices, IMAC is priced at $1.01, while AMS trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas AMS's P/E ratio is -6.14. In terms of profitability, IMAC's ROE is +1183.61%, compared to AMS's ROE of -0.09%. Regarding short-term risk, IMAC is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check AMS's competition here
IMAC vs CANO Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, IMAC is priced at $1.01, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CANO's P/E ratio is -0.01. In terms of profitability, IMAC's ROE is +1183.61%, compared to CANO's ROE of -1.49%. Regarding short-term risk, IMAC is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check CANO's competition here
IMAC vs FTRP Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, IMAC is priced at $1.01, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas FTRP's P/E ratio is -1.22. In terms of profitability, IMAC's ROE is +1183.61%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, IMAC is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check FTRP's competition here
IMAC vs TOIIW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, TOIIW has a market cap of 7.9M. Regarding current trading prices, IMAC is priced at $1.01, while TOIIW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas TOIIW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to TOIIW's ROE of +21.04%. Regarding short-term risk, IMAC is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check TOIIW's competition here
IMAC vs PIII Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, PIII has a market cap of 7.3M. Regarding current trading prices, IMAC is priced at $1.01, while PIII trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas PIII's P/E ratio is -0.04. In terms of profitability, IMAC's ROE is +1183.61%, compared to PIII's ROE of -3.18%. Regarding short-term risk, IMAC is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check PIII's competition here
IMAC vs MODV Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, IMAC is priced at $1.01, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas MODV's P/E ratio is -0.03. In terms of profitability, IMAC's ROE is +1183.61%, compared to MODV's ROE of +1.84%. Regarding short-term risk, IMAC is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check MODV's competition here
IMAC vs GBNH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, IMAC is priced at $1.01, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas GBNH's P/E ratio is -0.06. In terms of profitability, IMAC's ROE is +1183.61%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, IMAC is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check GBNH's competition here
IMAC vs RHE-PA Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, IMAC is priced at $1.01, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, IMAC's ROE is +1183.61%, compared to RHE-PA's ROE of -0.04%. Regarding short-term risk, IMAC is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check RHE-PA's competition here
IMAC vs RHE Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, IMAC is priced at $1.01, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas RHE's P/E ratio is -1.79. In terms of profitability, IMAC's ROE is +1183.61%, compared to RHE's ROE of +0.06%. Regarding short-term risk, IMAC is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check RHE's competition here
IMAC vs ATIP Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, IMAC is priced at $1.01, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas ATIP's P/E ratio is -0.03. In terms of profitability, IMAC's ROE is +1183.61%, compared to ATIP's ROE of +0.23%. Regarding short-term risk, IMAC is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check ATIP's competition here
IMAC vs TALKW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, TALKW has a market cap of 2.9M. Regarding current trading prices, IMAC is priced at $1.01, while TALKW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas TALKW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, IMAC is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check TALKW's competition here
IMAC vs IMACW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, IMAC is priced at $1.01, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas IMACW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, IMAC is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check IMACW's competition here
IMAC vs SYRA Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, SYRA has a market cap of 1M. Regarding current trading prices, IMAC is priced at $1.01, while SYRA trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas SYRA's P/E ratio is -1.12. In terms of profitability, IMAC's ROE is +1183.61%, compared to SYRA's ROE of -0.51%. Regarding short-term risk, IMAC is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check SYRA's competition here
IMAC vs MNDR Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, MNDR has a market cap of 823.8K. Regarding current trading prices, IMAC is priced at $1.01, while MNDR trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas MNDR's P/E ratio is -0.05. In terms of profitability, IMAC's ROE is +1183.61%, compared to MNDR's ROE of -1.29%. Regarding short-term risk, IMAC is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check MNDR's competition here
IMAC vs CCM Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, CCM has a market cap of 528.6K. Regarding current trading prices, IMAC is priced at $1.01, while CCM trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas CCM's P/E ratio is -0.67. In terms of profitability, IMAC's ROE is +1183.61%, compared to CCM's ROE of +0.07%. Regarding short-term risk, IMAC is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check CCM's competition here
IMAC vs BACK Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, BACK has a market cap of 212.3K. Regarding current trading prices, IMAC is priced at $1.01, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas BACK's P/E ratio is -0.02. In terms of profitability, IMAC's ROE is +1183.61%, compared to BACK's ROE of +1.05%. Regarding short-term risk, IMAC is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check BACK's competition here
IMAC vs NVOS Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, NVOS has a market cap of 61.2K. Regarding current trading prices, IMAC is priced at $1.01, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas NVOS's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, IMAC is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check NVOS's competition here
IMAC vs NIVFW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, NIVFW has a market cap of 35.3K. Regarding current trading prices, IMAC is priced at $1.01, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas NIVFW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to NIVFW's ROE of +1.17%. Regarding short-term risk, IMAC is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check NIVFW's competition here
IMAC vs PIIIW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, PIIIW has a market cap of 19.3K. Regarding current trading prices, IMAC is priced at $1.01, while PIIIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas PIIIW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to PIIIW's ROE of -3.18%. Regarding short-term risk, IMAC is more volatile compared to PIIIW. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check PIIIW's competition here
IMAC vs IONM Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, IMAC is priced at $1.01, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas IONM's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to IONM's ROE of +5.28%. Regarding short-term risk, IMAC is more volatile compared to IONM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check IONM's competition here
IMAC vs TVTY Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas TVTY's P/E ratio is 19.06. In terms of profitability, IMAC's ROE is +1183.61%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, IMAC is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check TVTY's competition here
IMAC vs DCGOW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas DCGOW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to DCGOW's ROE of -0.17%. Regarding short-term risk, IMAC is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check DCGOW's competition here
IMAC vs TLMDW Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas TLMDW's P/E ratio is N/A. In terms of profitability, IMAC's ROE is +1183.61%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, IMAC is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check TLMDW's competition here
IMAC vs TLMD Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas TLMD's P/E ratio is -1.60. In terms of profitability, IMAC's ROE is +1183.61%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, IMAC is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check TLMD's competition here
IMAC vs SLHGP Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, IMAC's ROE is +1183.61%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, IMAC is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check SLHGP's competition here
IMAC vs HNGR Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas HNGR's P/E ratio is 19.71. In terms of profitability, IMAC's ROE is +1183.61%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, IMAC is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check HNGR's competition here
IMAC vs DVCR Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas DVCR's P/E ratio is 28.34. In terms of profitability, IMAC's ROE is +1183.61%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, IMAC is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check DVCR's competition here
IMAC vs SLHG Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas SLHG's P/E ratio is -1.48. In terms of profitability, IMAC's ROE is +1183.61%, compared to SLHG's ROE of N/A. Regarding short-term risk, IMAC is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for IMAC.Check SLHG's competition here
IMAC vs NFH Comparison February 2026
IMAC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAC stands at 33.1M. In comparison, NFH has a market cap of 0. Regarding current trading prices, IMAC is priced at $1.01, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAC currently has a P/E ratio of -2.27, whereas NFH's P/E ratio is -19.75. In terms of profitability, IMAC's ROE is +1183.61%, compared to NFH's ROE of -0.06%. Regarding short-term risk, IMAC is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAC.Check NFH's competition here